Evidence map›Paper›PMID 38462517›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Hereditary Coproporphyria in Which the Patient's Course Improved after the Discontinuation of Givosiran.

Nobuaki Ozaki, Yuri Hayashi, Atsushi Kiyota

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nobuaki OzakiDivision of Endocrinology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Japan.
Yuri HayashiDivision of Endocrinology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Japan.
Atsushi KiyotaDivision of Endocrinology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary coproporphyria (HCP) is caused by a partial deficiency of coproporphyrinogen oxidase during heme biosynthesis. Givosiran is approved for the treatment of acute hepatic porphyria. We herein report the case of a 47-year-old woman with HCP. Monthly givosiran administration improved her subjective symptoms and reduced her δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels to the normal range. However, givosiran was discontinued after six months due to a decreased renal function. The patient's ALA and PBG levels remained within the normal ranges, and her HCP-related symptoms resolved more than 2 years after the discontinuation of givosiran.

Indexed as

Aminolevulinic AcidCoproporphyria, HereditaryAcetylgalactosamineFemaleHumansMiddle AgedPorphobilinogenPyrrolidinesTreatment OutcomeAcetylgalactosamineAminolevulinic AcidgivosiranPorphobilinogenPyrrolidinesgivosiranhereditary coproporphyriaporphobilinogenporphyriaδ-aminolevulinic acid

Identifiers

PMID38462517
PMCPMC11604377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.